Heparin and Fibrinolysis - Comparison of Subcutaneous Administration of Unfractionated and Low Molecular Weight Heparin

E Eriksson; I M Wollter; B Christenson; L Stigendal; B Risberg

doi:10.1055/s-0038-1642772

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1988; 59(02): 284-288
DOI: 10.1055/s-0038-1642772

Original Articles

Schattauer GmbH Stuttgart

Heparin and Fibrinolysis - Comparison of Subcutaneous Administration of Unfractionated and Low Molecular Weight Heparin

Authors

E Eriksson

^*The Department of Surgery I, Sahlgrenska sjukhuset, University of Göteborg, Sweden
I M Wollter

^**Coagulation Laboratory, Sahlgrenska sjukhuset, University of Güteborg, Sweden
B Christenson

^**Coagulation Laboratory, Sahlgrenska sjukhuset, University of Güteborg, Sweden
L Stigendal

^**Coagulation Laboratory, Sahlgrenska sjukhuset, University of Güteborg, Sweden
B Risberg

^*The Department of Surgery I, Sahlgrenska sjukhuset, University of Göteborg, Sweden

Abstract

PDF Download

Summary

The effects on the fibrinolytic system after a single s.c. bolus injection (at 9 a.m.) of either 5000 IU conventional heparin or 5000 anti-Xa U of a fractionated low molecular weight heparin (Fragmin, KabiVitrum, Sweden) were investigated in 9 healthy volunteers. The effects were compared to those of an injection of normal saline in 6 volunteers. Samples for biochemical analyses were taken regularily during 6 hours after drug or placebo administration.

In the coagulation system the following parameters were measured: Activated partial thromboplastin time (APTT), anti- Xa activity, thrombin time and fibrinogen. The fibrinolytic system was monitored by analysing: plasminogen, ɑ₂-antiplasmin, fibrinogen) degradation products (FDP), euglobulin clot lysis time (ECLT), tissue plasminogen activator (t-PA) activity, t-PA antigen and plasminogen activator inhibitor (PAI) activity. Injection of the 2 drugs was followed by elevations in APTT and anti-Xa activity, and were more pronounced for Fragmin than heparin. The fibrinolytic system exhibited a diurnal variation with decreasing PAI activity and increasing t-PA activity during the day. Volunteers receiving normal saline (placebo) showed a similar pattern. The results were unrelated to heparin.

It is concluded from this study that neither heparin nor Fragmin had any significant effect on the fibrinolytic parameters when measured after a single s.c. bolus injection since the observed variations were within the diurnal range.

Keywords

Unfractionated herpin - Low molecular weight heparin - Fibrinolysis - Tissue plasminogen activator

PDF (329 kb)

References

References
1 Björk J, Lindahl U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 1982; 48: 161-182
2 Andersson LO, Barrowcliffe TW, Homer E, Johnson EA, Soderstrom G. Molecular weight dependency of the heparin potenti-ated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 1979; 15: 531-541
3 Markwardt F, Klocking HP. Heparin-induced release of plasminogen activator. Haemostasis 1977; 6: 370-374
4 Coccheri S, Deroso V, Cavallaroni K. Activation of fibrinolysis by means of sulphated polysaccharides: Present status and perspectives. In: Progress in chemical fibrinolysis and thrombolysis. Davidson JF, Rowan RM, Samama MM, Desnoyers PC. (eds) New York: Raven Press; 1978. 3. 461-475
5 Vinazzer H. Heparin fractions and analogous. Rec Adv Blood Coagulation 1985; 4: 169-189
6 Vinazzer H, Moler M. A new low molecular weight heparin fragment (PK 10169) in vitro and in vivo studies. Thromb Res 1985; 40: 147-159
7 Stegnar M, Keber D. The effect of heparin on plasminogen activator release during venous occlusion. In: Progress in fibrinolysis. Davidsson IF, Donati MB, Cocceri S. (eds) Vol VI p 587 Churchill-Livingstone; Edingburgh: 1983
8 Schulman S, Granqvist E, Wiman B, Lockner D. Thrombolysis and fibrinolytic parameters during heparin treatment of deep vein Thrombosis. Thromb Res 1985; 39: 607-612
9 Arnesen H, Engebretsen LF, Ugland OM, Seljeflot J, Kierulf P. Increased fibrinolytic activity after surgery induced by low dose heparin. Thromb Res 1987; 45: 553-559
10 Molho PM, Dunn TL, Barzu TL, Soria C, Soria J, Dupuy E, Tobelem GM. Enhancement of fibrinolysis by a low molecular weight heparin in patients with thromboembolism and defective response to venous occlusion. In: Davidsson IF, Donati MB, Cocceri S. (eds) Progress in fibrinolysis; Vol VII 307-309 Churchill-Livingstone; Edinburgh: 1984
11 Nilsson IM. Blodnings och trombossjukdomar. Almqvist/Wiksell, Stockholm; Sweden: 1971: 224-224
12 Vermylen C, de Vreler RA, Verstraete M. A rapid enzymatic method for assay of fibrinogen-fibrin polymerisation time. Clin Chem Acta 1963; 8: 418-424
13 Soria J, Soria C, Samama M. Dosage du plasminogene a l’aide d’un substrat chromogene tripeptidique. Path Biol 1976; 24: 725-729
14 von Kaulla KN, Schultz RL. Methods for the evaluation of human fibrinolysis studies with two combined techniques. Am J Clin Path 1958; 29: 104-104
15 Gyzander E, Eriksson E, Teger-Nilsson A-C. A sensitive assay for tissue plasminogen activator activity in plasma, using adsorption on lysine-sepharose. Thromb Res 1984; 35: 547-558
16 Eriksson E, Risberg B. Measurement of tissue plasminogen activator in plasma A comparison of 3 methods and description of a new improved technique. Thomb Res 1987; 46: 213-223
17 Eriksson E, Ranby M, Gyzander E, Risberg B. Measurement of tissue plasminogen activator inhibitor in plasma utilizing polylysine as a stimulator. Submitted to Thromb Res.
18 Woolf C. Principles of Biometry. D. van Nostrand Inc; New York: 1968
19 Bergqvist D, Hedner S, jorin E, Holmer E. Anticoagulant effects of two types of low molecular weight heparin administrated subcutaneously. Thromb Res 1983; 32: 381-391
20 Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, Hoeg V, Aandahl M, Haugen K, Laerum F, Scheel BM, Sortland O, Vinje B. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Heamostasis 1986; 16: 30-37
21 Bratt G, Tornebohm L, Widlund L, Lockner D. Low molecular weight heparin (Kabi 2165, Fragmin): Pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986; 42: 613-620
22 Barrowcliffe TW, Curtis AD, Tomlinson TP, Hubbard AR, Johnson EA. Thomas D P. Standardisation of low molecular weight heparins: a collaborative study. Thromb Haemostas 1985; 54: 675-679
23 Jespersson J. The diurnal increase in euglobulin fibrinolytic activity in women using oral contraceptives and in normal women, and the generation of intrinsic fibrinolytic activity. Thromb Haemost 1986; 56: 183-188
24 Paques EP, Stohr HA, Heimburger N. Study on the mechanism of action of heparin and related substances on the fibrinolytic system: Relationship between plasminogen activators and heparin. Thromb Res 1986; 42: 797-807
25 Shimonaeva EE, Shimonaev GS, Aleshina ST. Heparin tissue plasminogen activator complex and some of its properties. Biochemistry. 1983. 48. 1456-1459
26 Kluft C, Jie AF H. Underestimation of tissue-type plasminogen activator in plasma when euglobulin fractions are used for assessment. Fibrinolysis 1986; Abstract 147-147
27 Kluft C, Verheijen JH, Rijken D-C, Chang GT G, Jie AF H, Onkelinx C. Diurnal fluctuations in the activity of the fast-acting t-PA inhibitor. In: Progress in fibrinolysis. Davidson IF, Donati MB, Coccheri S. (eds) Vol.VII pp 117-119 Churchill-Livingstone; Edinburgh: 1984
28 Neerstrand H, Ostergaard P, Bergqvist D, Martzsch T, Hedner U. tPA inhibitor, tPA: Ag, plasminogen and α₂-antiplasmin after low molecular weight heparin or standard heparin. Fibrinolysis 1987; 1: 39-43